Trial Profile

An Open-Label Extension Study Evaluating the Safety, Tolerability, PK, Immunogenicity, and Clinical Response of Multiple Doses of IV AK006 in Subjects with H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 10 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Mar 2025 According to an Allakos media release, company was discontinuing further development of AK006, restructuring operations to reduce costs and exploring strategic alternatives.
29 Jan 2025 Planned End Date changed from 1 Apr 2026 to 1 Jun 2025.
29 Jan 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Jun 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com